Ranibizumab for the treatment of neovascular AMD.

Ranibizumab for the treatment of neovascular AMD. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Ranibizumab for the treatment of neovascular AMD. Abstract Text:

P K Kaiser,D V Do,P K Kaiser,D V Do,

Age-related macular degeneration (AMD) is the leading cause of adult blindness among individuals aged 50 and older in the Western world, with the neovascular form of AMD responsible for the most severe and rapid visual loss. Although monotherapy with currently available treatments can slow the rate of loss of vision in eyes with neovascular AMD, they do not significantly improve vision. Vascular endothelial growth factor-A (VEGF-A) plays a critical role in the pathogenesis of neovascular AMD, and ranibizumab is a promising new treatment that targets all VEGF-A isoforms and their biologically active degradation products. Clinical trials have reported that ranibizumab treatment resulted in greater proportions of patients achieving a < 15 letter loss of visual acuity and improved vision at 12 and 24 months than control groups. The incidence of serious ocular and systemic adverse events was low in all ranibizumab trials to date. Currently, ranibizumab is the only treatment for neovascular AMD to demonstrate significant improvement in vision for many patients and represents a major advance in treating neovascular AMD.

Ranibizumab for the treatment of neovascular AMD. Publishing Authors By Initials

PK Kaiser,DV Do,PK Kaiser,DV Do,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Ranibizumab for the treatment of neovascular AMD. Journal Published:

PUBLICATION TYPE: Review

Journal: International journal of clinical practice

VOLUME: 61

Page Numbers: 501-9

Journal Abbreviation: Int. J. Clin. Pract.

ISSN: 1368-5031

DAY: 22

MONTH: Mar

YEAR: 2007

Ranibizumab for the treatment of neovascular AMD. Information

Number of References: 58

LANGUAGE: eng

NlmUniqueID: 9712381

Ranibizumab for the treatment of neovascular AMD. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Ranibizumab for the treatment of neovascular AMD. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Ranibizumab for the treatment of neovascular AMD.

AFFILIATION: Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Int J Clin Pract

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Ranibizumab for the treatment of neovascular AMD Related Publications

• "Click" xylosides initiate glycosaminoglycan biosynthesis in a mammalian cell line.
• A glutathione deficit alters dopamine modulation of L-type calcium channels via D2 and ryanodine receptors in neurons.
• A pilot of audio computer-assisted self-interview for youth reproductive health research in Vietnam.
• Adsorption of Water in Finite Length Carbon Slit Pore: Comparison between Computer Simulation and Experiment.
• Aluminium-salen luminophores as new hole-blocking materials for phosphorescent OLEDs.
• Appropriate volumes for adsorption isotherm studies: The absolute void volume, accessible pore volume and enclosing particle volume.
• Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer.
• Changes in motor activity and biomechanics during balance recovery following cutaneous and muscular deafferentation.
• Characteristic heats of adsorption for slit pore and defected pore models.
• Charcot spine in a person with congenital insensitivity to pain with anhydrosis: a case report of re-diagnosis.
• Collinear guided wave to leaky wave acoustooptic interactions in proton-exchanged LiNbO(3) waveguides.
• Effects of magnesium sulphate on intraoperative anaesthetic requirements and postoperative analgesia in gynaecology patients receiving total intravenous anaesthesia.
• Ethanol increases the activity of rat excitatory amino acid transporter type 4 expressed in Xenopus oocytes: role of protein kinase C and phosphatidylinositol 3-kinase.
• Evaluation of three algorithms to identify incident breast cancer in Medicare claims data.
• Glutamate-induced retinal lipid and protein damage: The protective effects of catechin.
• Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence.
• Internal iliac artery embolization before endovascular repair of aortoiliac aneurysms with a nitinol vascular occlusion plug.
• MR imaging of popliteal pterygium syndrome in pediatric patients.
• Multivariate causal attribution and cost-effectiveness of a national mass media campaign in the Philippines.
• Novel chlorotitanium complexes containing chiral tridentate schiff base ligands for ring-opening polymerization of lactide.
• Novel synthetic strategy for developing an isospecific unbridged metallocene system for propylene polymerization.
• Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
• Palliative radiation therapy for localized prostate symptoms in hormone refractory prostate cancer.
• Racial differences in self-reports of sleep duration in a population-based study.
• Ranibizumab for the treatment of neovascular AMD.
• Severe symptomatic vasospasm after rupture of an arteriovenous malformation.
• Substance use among a sample of foreign- and U.S.-born southeast Asians in an urban setting.
• The Compton source efficiency tracing method in liquid scintillation counting: A new standardization method using a TDCR counter with a Compton spectrometer.
• [Strengthening Causal Inference in Studies using Non-experimental Data: An Application of Propensity Score and Instrumental Variable Methods.]
• [Ulcus cruris--vascular etiology and surgical treatment options]